MedTrace Logo

An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma

NCT01684865 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2017-12-29

No results posted yet for this study

Summary

This prospective observational study will evaluate the safety and efficacy of first-line rituximab maintenance therapy in participants with follicular non-Hodgkin's lymphoma. Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will be followed for a maximum of 3 years or until disease progression occurs.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

Rituximab

Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-22
Primary Completion
2017-11-27
Completion
2017-11-27

Countries

  • North Macedonia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01684865 on ClinicalTrials.gov